ZIOPHARM Oncology

ZIOPHARM Oncology, Inc., is a biopharmaceutical company focused on the discovery and development of new cancer therapies. We are applying the latest technologies in cancer research to develop safer, more precise therapeutics to improve care and quality of life for patients.
Company Growth (employees)
Type
Public
HQ
Boston, US
Size (employees)
36 (est)
ZIOPHARM Oncology is headquartered in Boston, US

Key People/Management at ZIOPHARM Oncology

Jonathan Lewis

Jonathan Lewis

CEO
Caesar J. Belbel

Caesar J. Belbel

CLO

ZIOPHARM Oncology Office Locations

ZIOPHARM Oncology has an office in Boston

ZIOPHARM Oncology Financials and Metrics

ZIOPHARM Oncology Financials

ZIOPHARM Oncology's revenue was reported to be $6.9 m in FY, 2016
USD

Net income (Q1, 2017)

(15.5 m)

EBIT (Q1, 2017)

(14 m)

Market capitalization (20-Oct-2017)

732.4 m

Cash (31-Mar-2017)

66.4 m
ZIOPHARM Oncology's current market capitalization is $732.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

800 k1.4 m4.3 m6.9 m

Revenue growth, %

72%216%58%

R&D expense

157.8 m

General and administrative expense

14.4 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

12 m

General and administrative expense

3 m2.8 m4.3 m7.1 m3.1 m3.8 m3.7 m3.5 m3.6 m

Operating expense total

3 m2.8 m4.3 m7.1 m3.1 m3.8 m3.7 m3.5 m15.6 m

EBIT

(11.2 m)(11.9 m)(78.2 m)(14.2 m)(18.2 m)(12 m)(131.2 m)(10.9 m)(14 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

68.2 m42.8 m140.7 m81.1 m

Accounts Receivable

508.4 m

Inventories

1.9 m1.1 m11.4 m23.8 m

Current Assets

70.3 m44.1 m152.5 m104.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

53 m46.1 m129.7 m118.6 m163.8 m124.8 m109 m94.7 m66.4 m

Current Assets

54 m47.8 m130.6 m123.1 m172.5 m140.4 m126.7 m115.7 m92.8 m

PP&E

683 k654 k426 k321 k262 k667 k682 k825 k1.1 m

Total Assets

55.3 m49.1 m131.6 m124 m173.4 m141.7 m128 m117.1 m94.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(57.1 m)(31.8 m)(120.1 m)(165.3 m)

Depreciation and Amortization

738 k462 k357 k290 k

Inventories

5 m809 k(10 m)(12 m)

Accounts Payable

(1.1 m)1.6 m4 k(1.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.3 m)(21.4 m)(78.2 m)(92.4 m)(110.6 m)(12 m)(143.2 m)(154.1 m)(15.5 m)

Depreciation and Amortization

217 k339 k122 k236 k295 k72 k155 k227 k79 k

Accounts Payable

25 k1.5 m(1.2 m)1.1 m2.2 m(100 k)23 k(194 k)70 k

Cash From Operating Activities

(16.3 m)(26.8 m)(9.7 m)(21.4 m)23.8 m(16.1 m)(31.2 m)(45.3 m)(14.3 m)
Y, 2017

Financial Leverage

-1 x
Show all financial metrics

ZIOPHARM Oncology Market Value History

Traffic Overview of ZIOPHARM Oncology

ZIOPHARM Oncology Company Life and Culture

You may also be interested in